Collins Helen Louise 4

What Happened

• Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics (ELVN), exercised stock options for 5,000 shares at $2.48 per share (cost $12,400) and sold 5,000 shares in open-market trades the same day for total gross proceeds of approximately $219,017 (three blocks: 1,268 / 2,599 / 1,133 shares). The filing also shows a conversion/settlement of 5,000 RSUs (restricted stock units) into shares (no cash reported).
• The sales were executed June 17, 2026 and were carried out under a Rule 10b5-1 trading plan adopted by Collins on October 19, 2025.

Key Details

• Transaction date: June 17, 2026; Form 4 filed June 22, 2026.
• Option exercise: 5,000 shares acquired at $2.48 each (total $12,400). Footnote confirms all option shares were fully vested and exercisable as of the date.
• Open-market sales: total 5,000 shares sold in multiple trades for aggregate proceeds of ~ $219,017:
  • 1,268 shares at a weighted avg $42.83 (proceeds ≈ $54,305; trades ranged $42.295–$43.2752)
  • 2,599 shares at a weighted avg $43.87 (proceeds ≈ $114,018; trades ranged $43.30–$44.2925)
  • 1,133 shares at a weighted avg $44.74 (proceeds ≈ $50,694; trades ranged $44.3005–$44.95)
• RSU conversion: 5,000 RSUs converted to shares (each RSU represents a contingent right to one share); no cash shown for that line.
• Filing notes: sales/exercise effected pursuant to a 10b5-1 plan (adopted Oct 19, 2025). The filing shows weighted-average prices and includes footnotes offering to provide per-trade price details upon request.
• Shares owned after transaction: not disclosed in the filing.

Context

• Derivative explanation: “M” indicates option exercise/derivative conversion — Collins exercised options to acquire shares. Because option exercise and sales occurred on the same day, the transactions functionally monetize vested option shares (often called a cashless exercise/monetization when shares are sold immediately).
• 10b5-1 plan: sales under an established 10b5-1 plan are pre-set and generally indicate routine selling, not necessarily a change in insider view.
• Timeliness: Form 4 was filed on June 22 for transactions dated June 17. Form 4s are normally due within two business days of a transaction; investors may want to confirm whether the filing was deemed timely by the SEC.